Promising Finding to Combat Autism

San Diego, CA

A group of researchers at Scintillon Institute in San Diego, California demonstrated a promising therapeutic intervention for autism in an animal model.  This study, published today in Nature Communications under the title of “NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism”, proposes a therapeutic strategy to mitigate the hallmarks of MEF2C haploinsufficiency syndrome (MCHS), a condition where patients who carry one copy of defective MEF2C gene suffer from severe neurological conditions including autism spectrum disorders, intellectual disabilities, and seizures.  

Neurons of normal versus mutant cells